Treatment of COVID-19 during esophageal cancer surgery: A case report
- VernacularTitle:食管癌围术期感染新型冠状病毒一例
- Author:
Yan ZHAO
1
;
Hui LI
1
;
Li GU
2
;
Bin YOU
1
Author Information
1. Department of Thoracic Surgery, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, P. R. China
2. Department of Infectious Diseases and Clinical Microbiology, Beijing Institute of Respiratory Medicine and Beijing Chao-Yang Hospital, Capital Medical University, Beijing, 100020, P. R. China
- Publication Type:Journal Article
- Keywords:
COVID-19;
esophageal cancer;
neoadjuvant therapy;
case report
- From:
Chinese Journal of Clinical Thoracic and Cardiovascular Surgery
2024;31(07):1074-1076
- CountryChina
- Language:Chinese
-
Abstract:
There is still a lack of experience in the perioperative strategy for esophageal cancer patients in China during the epidemic of COVID-19. In December 2022, a 59-year-old male patient with esophageal cancer was admitted to our department. He received 2 cycles of neoadjuvant therapy before surgery, and developed COVID-19 perioperatively. After treatment, the infection symptoms of the patient were improved, and the postoperative recovery was satisfactory.
